Abstract 1279
Background
The newly created Department of Oncology Nurse Coordinators, in this case the Digestive Oncology department, ONCDOD, at the Jules Bordet Institute, allows patients, mainly the newly diagnosed, to early personalized medicine. The aim is to orient the patients to all the services available and implicated to his/her care; to explain the treatment, procedures for therapies and answer questions; to be present for the patient and his family so as to create a climate of confidence, comfort and security.
Methods
60 newly diagnosed digestive patients were followed by the Nurse Coordinator in the year 2018. The necessary care requirements for this group of patients were identified, recorded and analysed in collaboration with the multidisciplinary team. With the help of an exhaustive data on the patient, all the Oncology Nurse Coordinator’s activities were reported in a unique, accessible electronic patient’s file.
Results
Thanks to knowledge of the patient’s medical situation, but also to his psychological and socioeconomic environment, the interventions of the Oncology Nurse Coordinator allowed a more fluid path of diagnosis and treatment, rapid and efficient care of treatment side effects, avoid unnecessary hospitalization and ensure more comfort and security for the patient.
Conclusions
The daily follow-up of newly diagnosed digestive patients, allowed a more effective taking care of patients from the diagnosis. The patients showed confidence and serenity knowing that they can call one single person, anytime, in the hospital for all their questions and needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fouad Awada.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract